Navigation Links
OrbusNeich Receives CE Mark Approval for Sapphire(TM) 1.25MM PTCA Dilatation Catheter
Date:4/7/2008

Small-Diameter Balloon Catheter Designed for Pre-Dilatation of Tight,

Calcified CTO Lesions That Require Best Crossability

HONG KONG, April 7, 2008 /PRNewswire/ -- OrbusNeich today announced that it has received CE Mark approval for the Sapphire(TM) 1.25mm PTCA dilatation catheter.

Slated for immediate roll-out to the interventional cardiology community, Sapphire 1.25mm is a small-diameter balloon catheter designed specifically for the pre-dilatation of tight, calcified chronic total occlusion (CTO) lesions that require the best crossability. The product provides physicians with enhanced pushability and superior kink resistance. The Sapphire 1.25mm is the only balloon available in a 5mm length. In addition, 8mm, 10mm and 15mm lengths are also offered.

"The Sapphire 1.25mm balloon is easily deliverable with good pushability, and may be considered a first choice in highly stenotic lesions," said Professor Tan Huay Cheem of the University Hospital in Singapore.

OrbusNeich designs, develops, manufactures and markets innovative medical devices for the treatment of vascular diseases. The company's product portfolio includes the Genous(TM) Bio-engineered R stent(TM), an antibody-coated device that is the first-ever stent to capture a patient's endothelial progenitor cells (EPCs) to accelerate the natural healing process following placement. Other products are stents, balloons and guiding catheters marketed under the names of Blazer(TM), R stent(TM), Sapphire(TM), Avita(TM), Avita HP(TM), SafeCut(TM), Lumina(TM) and Saffron.

A global company, OrbusNeich is headquartered in Hong Kong and has operations in Fort Lauderdale, Fla.; Hoevelaken, The Netherlands; Tokyo; and Shenzhen, China. OrbusNeich, which has provided cardiology devices to physicians through its predecessor companies since 1979, today supplies products to interventional cardiologists in more than 60 countries. For more information, visit http://www.OrbusNeich.com.


'/>"/>
SOURCE OrbusNeich
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. 5,000 Patients Treated With OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) Now Enrolled in Real-Life Use Global Registry
2. Data from Patient Subsets of e-HEALING, a Worldwide Registry, Support Use of OrbusNeichs Genous(TM) Bio-Engineered R Stent(TM) as Alternative to Drug- Eluting Stents
3. Biopure Receives Comment Letter From U.K. Regulatory Body on Marketing Application for Hemopure(R)
4. iCAD Receives FDA Approval for Its SecondLook Digital for Use With Fujis Digital Mammography System
5. FORSTEO(R) Receives Approval from the European Commission for the Treatment of Glucocorticoid-Induced Osteoporosis
6. Portrait(R) Plasma Receives Clearance from the FDA to Treat Acne Scars
7. CryoCor Reports Going Concern Statement and Receives Notification From Nasdaq Relating to Minimum Stockholders Equity
8. Western Reserve Heart Care Receives ICANL Nuclear Medicine Accreditation
9. AIDS Activist Gregg Gonsalves Receives $100,000 Leadership Award
10. Emageon Receives Best in KLAS Cardiology PACS Award
11. London Luxury Receives Asthma & Allergy Friendly(TM) Certification for Several of Its Bedding Products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... ... January 20, 2017 , ... Source Vitál Apothecary, a skin and ... essential oils, announced the company had a successful visit to the 2017 ECRM Diet, ... gives companies that work in the nutritional, sports and health industries a chance to ...
(Date:1/20/2017)... ... January 20, 2017 , ... Bionic Sports Nutrition LLC, an American ... announced it had a successful January ECRM Trade Show in Hilton Head, SC. ... which allows it to provide its products to all clients at reasonable prices. At ...
(Date:1/20/2017)... ... January 20, 2017 , ... ... enhance people’s everyday lives, recently attended the January ECRM Trade Show in Hilton ... is known for its large range of supplements that keep the body functioning ...
(Date:1/20/2017)... ... 2017 , ... Michael and Betsy Brauser celebrated 5 years of Betsy’s participation ... trial has been life-saving as she has been on the trial for more ... diagnosed with ovarian cancer in 2009. She underwent standard chemotherapy but a year later ...
(Date:1/20/2017)... , ... January 20, 2017 , ... ... and its sugar-free alternative VW+ 002. The drinks have been produced in collaboration ... conditions to perform during your workout. , After a successful launch in Sweden ...
Breaking Medicine News(10 mins):
(Date:1/21/2017)... Jan 20, 2017 Research and Markets ... Testing Market By Type of Test (Tumor, Clinical Chemistry, Microbiology, ... Type of Diseases (Tuberculosis, Influenza, Cancer, HIV/AIDS etc.), Forecast to ... ... for healthcare services, market segments, especially clinical lab testing, which ...
(Date:1/21/2017)... Calif. , Jan. 20, 2017 ARMO ... 1b clinical data on the Company,s lead investigational immuno-oncology ... Symposium, co-sponsored by the American Society of Clinical Oncology ... San Francisco, CA. "AM0010 ... activated CD8 + T cells in the blood ...
(Date:1/21/2017)... YORK , Jan. 20, 2017  Faruqi & Faruqi, ... KemPharm, Inc. ("KemPharm" or the "Company") (NASDAQ: KMPH ... the Company and certain officers and directors and underwriters of ... to seek the role of lead plaintiff. The ... District Court for Johnson County ...
Breaking Medicine Technology: